Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- PMID: 34861372
- DOI: 10.1016/j.annonc.2021.11.012
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Keywords: antibody drug conjugates; bladder cancer; fibroblast growth factor receptor inhibitors; immune checkpoint inhibitors; platinum-based chemotherapy; urothelial carcinoma.
Conflict of interest statement
Disclosure TP has received research funding from Merck Serono, Merck, Sharp & Dohme (MSD), Roche, Bristol Myers Squibb (BMS), AstraZeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelixis and Eisai and honoraria from Merck Serono, MSD, Roche, BMS, AstraZeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelixis and Eisai; JB has received honoraria for participation in advisory boards from Pfizer, AstraZeneca, Merck and BMS, invited speaker fees from Merck, Genentech and MSD, royalties from UpToDate, institutional research funding as principal investigator (PI) for MSD and Pfizer, research funding from Takeda and non-remunerated activities as steering committee member of the IMvigor 011 study; EC has received honoraria from Jansen for invited speaker and non-remunerated activities in an advisory role for the EAU guidelines; MDS has received honoraria for participation in advisory boards and as an invited speaker for 4D, AAA, Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, BMS, EISAI, Ferring, Immunomedics, Ipsen, Janssen, MSD, Merck Serono, Novartis, Pfizer, Pierre Fabre Oncology, Roche, Sandoz, Sanofi, SeaGen and Amgen and institutional research as PI and steering committee member for Basilea, AstraZeneca, MSD, Merck, EISAI, Astellas, SeaGen, Exelixis, Ipsen, Roche, Immunomedics, Janssen and Calithera; RH has received honoraria for participation in advisory boards for Roche, Nektar, BMS, MSD and Astellas, expert testimony for National Institute of Clinical Excellence and partnership in the Cancer Centre London, institutional royalties received from Janssen, research grants from MSD and Roche, local PI for Roche, MSD, Basilea and Cancer Research UK; patient funding from Astellas and steering committee member with Cancer Research UK; YL has received honoraria for lectures, presentations, speaker’s bureau, manuscript writing or educational events from BMS, Pfizer, Merck KGaA, MSD, AstraZeneca, Roche, Jansen, Astellas, Seattle Genetics and Immunomedics and support for attending meetings and/or travel grants from BMS, Roche, AstraZeneca, MSD and Pfizer; AN has received institutional research grants from Merck, AstraZeneca, Ipsen and BMS and has undertaken personal research as a steering committee member for Roche, Janssen, Bayer, Astellas, AstraZeneca, Merck and Clovis Oncology; BPV has received honoraria for advisory boards for Pfizer, Astellas Pharma, BMS, Ipsen, EUSA Pharma, Sanofi-Aventis and Merck and has been an invited speaker for Janssen, Pfizer, BMS, Roche, Bayer, EUSA Pharma, MSD and Merck; AR has received honoraria for advisory boards for Pfizer, Merck GA, BMS, Ipsen, MSD and AstraZeneca and has been an invited speaker for Pfizer, Merck GA, BMS, Ipsen and MSD and has received institutional grants from Pfizer, Merck GA and Ipsen; SFS has received honoraria for participation in advisory boards for Astellas, Janssen, MSD, AstraZeneca, Bayer, BMS, Cepheid, Ferring Pharmaceuticals, Ipsen, Lilly, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda and UroGen; BS has received honoraria from Ellipses, Ipsen, Merck, Pfizer and Roche and has received travel and research funding from BMS, Genentech, MSD, Pfizer and Roche; MSvdH has received honoraria (paid to institute) for participation in advisory boards for BMS, Roche, Seagen, AstraZeneca, Janssen, Pfizer and MSD, stock ownership with Gilead; and institutional research funding from BMS, Roche, AstraZeneca and 4SC; SG has received personal honoraria for participation in advisory boards for Sanofi, Orion, Roche, Amgen, MSD and Aranda; other honoraria from RSI Televisione Svizzera Italiana); has been an invited speaker for ESMO, SAKK, SAMO, Orikata and CACA-GU, speaker’s bureau for Janssen Cilag; travel grant from ProteoMEdiX, institutional honoraria for advisory boards for Bayer, Janssen Cilag, Roche and AAA International including Independent Data Monitoring Committee; steering committee for Amgen, Menarini Silicon Biosystems, Astellas Pharma, Tolero Pharmaceuticals, MSD, Pfizer, Telixpharma, BMS and Orion and has received a patent, royalties and other intellectual property from Method for Biomarker WO2009138392.
Comment in
-
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol. 2022 May;33(5):561. doi: 10.1016/j.annonc.2022.01.075. Epub 2022 Feb 2. Ann Oncol. 2022. PMID: 35121006 No abstract available.
-
Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape.Ann Oncol. 2022 Mar;33(3):242-243. doi: 10.1016/j.annonc.2022.01.073. Ann Oncol. 2022. PMID: 35151428 No abstract available.
Similar articles
-
[Innovations in systemic treatment of urothelial carcinoma].Bull Cancer. 2020 Jun;107(5S):S6-S16. doi: 10.1016/S0007-4551(20)30273-3. Bull Cancer. 2020. PMID: 32620209 Review. French.
-
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.Ann Oncol. 2024 Jun;35(6):485-490. doi: 10.1016/j.annonc.2024.03.001. Epub 2024 Mar 13. Ann Oncol. 2024. PMID: 38490358 No abstract available.
-
Evolving systemic management of urothelial cancers.Curr Opin Oncol. 2023 May 1;35(3):186-199. doi: 10.1097/CCO.0000000000000942. Epub 2023 Mar 14. Curr Opin Oncol. 2023. PMID: 36966497 Review.
-
Current Therapy for Metastatic Urothelial Carcinoma.Hematol Oncol Clin North Am. 2021 Jun;35(3):469-493. doi: 10.1016/j.hoc.2021.02.010. Epub 2021 Apr 10. Hematol Oncol Clin North Am. 2021. PMID: 33958146 Review.
-
The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.Clin Genitourin Cancer. 2021 Jun;19(3):183-193. doi: 10.1016/j.clgc.2020.11.006. Epub 2020 Dec 2. Clin Genitourin Cancer. 2021. PMID: 33558159 Review.
Cited by
-
Targeting FGFR for cancer therapy.J Hematol Oncol. 2024 Jun 3;17(1):39. doi: 10.1186/s13045-024-01558-1. J Hematol Oncol. 2024. PMID: 38831455 Free PMC article. Review.
-
Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.Clin Med Insights Oncol. 2024 May 30;18:11795549241257238. doi: 10.1177/11795549241257238. eCollection 2024. Clin Med Insights Oncol. 2024. PMID: 38827522 Free PMC article.
-
Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.Front Immunol. 2024 May 10;15:1401214. doi: 10.3389/fimmu.2024.1401214. eCollection 2024. Front Immunol. 2024. PMID: 38799450 Free PMC article.
-
Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge.Cancer Manag Res. 2024 May 17;16:467-475. doi: 10.2147/CMAR.S445529. eCollection 2024. Cancer Manag Res. 2024. PMID: 38774494 Free PMC article. Review.
-
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.PLoS One. 2024 May 10;19(5):e0302548. doi: 10.1371/journal.pone.0302548. eCollection 2024. PLoS One. 2024. PMID: 38728337 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical